IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent Anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment

Marschall M, Peelen E, Müller R, Wangen C, Wagner S, Muehler A, Groeppel M, Vitt D, Kohlhof H, Hahn F (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Multiple sclerosis journal Sage

Publisher: SAGE PUBLICATIONS LTD

City/Town: LONDON

Pages Range: 364-365

Conference Proceedings Title: MULTIPLE SCLEROSIS JOURNAL

Authors with CRIS profile

Manfred Marschall Lehrstuhl für Klinische und Molekulare Virologie Sören Wagner Department of Anaesthesiology Friedrich Hahn Institute of Clinical and Molecular Virology

Involved external institutions

Immunic AG DE Germany (DE)

How to cite

APA:

Marschall, M., Peelen, E., Müller, R., Wangen, C., Wagner, S., Muehler, A.,... Hahn, F. (2021). IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent Anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment. In MULTIPLE SCLEROSIS JOURNAL (pp. 364-365). LONDON: SAGE PUBLICATIONS LTD.

MLA:

Marschall, Manfred, et al. "IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent Anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment." Proceedings of the MULTIPLE SCLEROSIS JOURNAL LONDON: SAGE PUBLICATIONS LTD, 2021. 364-365.

BibTeX: Download